Company intelligence / Profile preview

Imagilin Technology

Frederick, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Imagilin has developed a patented, plant-based, non-spore forming probiotic strain that can withstand high temperatures (up to 185℉/85℃) and stomach acids, with demonstrated stability at room temperature for up to two years

Therapeutic areas: ImmunologyOtherGastroenterology
Modalities: Live biotherapeutic product therapy
Industry: Non-Drug Biotech

Partnerships

Walter Reed Army Institute of ResearchUnited States Department of Agriculture (Beltsville)University of Maryland College ParkUniversity of Maryland School of MedicineNorth Texas UniversityMarion Scott Dupont Equine Medical CenterVirginia Polytechnic InstituteHood CollegeMerimax (Brazilian biotechnology company)

Beyond the preview

Go deeper on Imagilin Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imagilin Technology.

Explore the full profile